Drug-Eluting Balloon Catheters Market Size & Growth Forecast 2027–2036, By Segments (Product, Material, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Drug-Eluting Balloon Catheters Market size was more than USD 749.66 Million in 2026 and is set to grow at 10.49% CAGR between 2027 and 2036, exceeding USD 2.03 Billion by 2036. The industry revenue for 2027 is calculated at USD 816.45 Million.
Get more details on this report
Request Free Sample ReportDrug-Eluting Balloon Catheters Market Intelligence Snapshot
Regional Market Dynamics
- North America held 45.26% in 2026, supported by advanced cardiovascular infrastructure, established interventional expertise, and strong adoption of minimally invasive vascular procedures.
- Asia Pacific is expanding through cardiovascular infrastructure development, rising vascular disease burden, greater access to specialized care, and increasing adoption of minimally invasive interventions.
Segment Momentum
- Peripheral vascular disease drug-eluting balloon catheters accounted for 58.62% of the market in 2026, driven by growing use in minimally invasive peripheral interventions and demand for durable outcomes with reduced restenosis.
- Ambulatory surgical centers are the fastest-growing end-use segment as more vascular procedures shift to outpatient settings, supported by minimally invasive techniques, shorter recovery times, and cost-efficient care models.
Market Expansion Drivers
- Rising cardiovascular and peripheral artery disease prevalence driving minimally invasive treatment demand
- Increasing preference for minimally invasive procedures accelerating adoption of advanced catheter technologies
- Technological advancements in drug-eluting delivery systems improving treatment efficacy and clinical outcomes
Leading Market Participants
- Prominent players in the drug-eluting balloon catheters market include Medtronic plc (Ireland), Boston Scientific Corporation (United States), B. Braun Melsungen AG (Germany), Biotronik SE & Co. KG (Germany), Becton, Dickinson and Company (United States), Biosensors International Group, Ltd. (Singapore), Terumo Corporation (Japan), Lepu Medical Technology (Beijing) Co., Ltd. (China), iVascular S.L.U. (Spain), MedAlliance SA (Switzerland)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 749.66 Million
- 2027 Estimated Market Size: USD 816.45 Million
- Projected Market Size: USD 2.03 Billion by 2036
- Growth Forecast: 10.49% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Peripheral Vascular Disease Drug-Eluting Balloon Catheters (Product) | Polyurethane (Material) | Hospitals and Clinics (End Use)
- Emerging Opportunity Segment: Coronary Artery Disease Drug-Eluting Balloon Catheters (Product) | Polyurethane (Material) | Ambulatory Surgical Centers (End Use)
Market Growth Drivers and Industry Trends
Rising cardiovascular and peripheral artery disease prevalence driving minimally invasive treatment demand
The growing incidence of cardiovascular and peripheral artery diseases is increasing the need for effective treatment options that reduce procedural complexity while improving patient outcomes. The drug-eluting balloon catheters market growth is driven by rising demand for minimally invasive interventions that restore blood flow without requiring more extensive surgical procedures. Healthcare providers are increasingly adopting therapies that shorten recovery times, minimize procedural risks, and provide effective management of vascular conditions across diverse patient populations.
Increasing preference for minimally invasive procedures accelerating adoption of advanced catheter technologies
Healthcare systems continue to prioritize minimally invasive techniques that enhance patient safety while improving procedural efficiency across cardiovascular interventions. This shift will propel the drug-eluting balloon catheters market growth by encouraging greater use of advanced catheter technologies that offer precise drug delivery alongside vessel dilation during treatment. Physicians also value these solutions for their ability to simplify complex procedures while supporting faster patient recovery and reducing hospitalization requirements.
Technological advancements in drug-eluting delivery systems improving treatment efficacy and clinical outcomes
Continuous innovation in catheter engineering and drug delivery technologies is improving the therapeutic performance of vascular intervention devices. Advancements in coating technologies, controlled drug release mechanisms, and device design will strengthen the drug-eluting balloon catheters market by enabling more consistent drug transfer, enhanced lesion treatment, and improved procedural reliability. Ongoing product development is also expanding the range of clinical applications where these technologies can support effective vascular disease management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cardiovascular and peripheral artery disease prevalence driving minimally invasive treatment demand | 2% | High | North America, Europe | High | Near Term |
| Increasing preference for minimally invasive procedures accelerating adoption of advanced catheter technologies | 1.9% | High | North America, Asia Pacific | High | Near Term |
| Technological advancements in drug-eluting delivery systems improving treatment efficacy and clinical outcomes | 1.7% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for 45.26% of the drug-eluting balloon catheters market in 2026, supported by advanced cardiovascular care infrastructure and strong adoption of minimally invasive interventional procedures. The region benefits from established expertise in peripheral and coronary interventions, while increasing preference for less invasive treatment options supports the use of drug-eluting technologies. Continued emphasis on improving vascular disease management, along with access to specialized cardiac and interventional care, reinforces regional demand for these catheters.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to experience the fastest growth, supported by expanding cardiovascular healthcare infrastructure, increasing awareness of minimally invasive interventions, and improving access to specialized medical treatment. The growing burden of vascular diseases is encouraging healthcare providers to adopt more advanced interventional approaches, while investments in hospitals and catheterization facilities are broadening treatment availability. Rising healthcare expenditure and greater acceptance of drug-delivery technologies in vascular procedures are further creating opportunities for market expansion across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced Interventional AdoptionThe U.S. continues to prioritize drug-eluting balloon catheter adoption through expanding minimally invasive cardiovascular procedures and ongoing clinical evidence generation. Healthcare providers in the U.S. emphasize technologies that improve vessel patency while supporting efficient treatment pathways across complex peripheral and coronary interventions.
Germany 🇩🇪
Clinical Evidence IntegrationGermany emphasizes evidence-based adoption of drug-eluting balloon catheters through established cardiovascular centers and physician-led treatment protocols. German healthcare institutions continue evaluating devices that support restenosis management while aligning with evolving interventional cardiology practices.
Japan 🇯🇵
Precision Device UtilizationJapan focuses on incorporating drug-eluting balloon catheters into precision cardiovascular care, particularly for patients requiring minimally invasive treatment options. Clinical adoption in Japan is supported by strong demand for advanced catheter technologies with proven procedural performance.
South Korea 🇰🇷
Innovation-Driven ProceduresSouth Korea is strengthening the use of drug-eluting balloon catheters by integrating advanced interventional technologies into specialized cardiovascular hospitals. Local healthcare providers in South Korea are prioritizing devices that improve procedural efficiency and support modern vascular treatment strategies.
France 🇫🇷
Hospital-Based Intervention FocusFrance continues to reinforce hospital adoption of drug-eluting balloon catheters as cardiovascular specialists seek effective endovascular treatment options. French healthcare systems emphasize clinically validated devices that enhance patient outcomes while supporting standardized intervention protocols.
Italy 🇮🇹
Peripheral Vascular ExpansionItaly is expanding the clinical use of drug-eluting balloon catheters across peripheral vascular interventions as healthcare providers modernize treatment approaches. Hospitals in Italy are increasingly adopting technologies that reduce repeat procedures and complement established endovascular practices.
Segment Leadership and Growth Trends
Drug-Eluting Balloon Catheters Market Share (%), Product, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Peripheral Vascular Disease Drug-Eluting Balloon Catheters (Largest Segment) vs Coronary Artery Disease Drug-Eluting Balloon Catheters (Fastest-Growing Segment)
The peripheral vascular disease drug-eluting balloon catheters segment dominated the drug-eluting balloon catheters market, accounting for a share of 58.62% in 2026. Its leading position is supported by the increasing clinical use of minimally invasive procedures for peripheral artery disease and the growing preference for drug-coated technologies that help reduce restenosis while preserving vessel flexibility. The segment also benefits from the rising demand for effective treatment options in complex peripheral vascular interventions, where durable clinical outcomes and shorter recovery periods are key priorities.
The coronary artery disease drug-eluting balloon catheters segment is the fastest-growing category as healthcare providers increasingly adopt vessel-preserving interventional approaches for selected coronary lesions. Advances in balloon coating technologies, expanding clinical evidence supporting drug-eluting balloons in coronary applications, and the growing emphasis on reducing permanent implant use are encouraging broader utilization. Continuous innovation in interventional cardiology and increasing adoption of minimally invasive coronary procedures are expected to further strengthen segment growth.
Material Segment Analysis: Polyurethane (Largest & Fastest-Growing Segment)
The drug-eluting balloon catheters market was led by the polyurethane segment, which held the largest share of 38.12% in 2026 while also emerging as the fastest-growing material category. Polyurethane is widely preferred because it offers an effective balance of flexibility, durability, and biocompatibility, enabling controlled drug delivery and reliable balloon performance during vascular interventions. Its compatibility with advanced catheter designs and manufacturing processes further supports its widespread adoption as demand grows for high-performance devices capable of improving procedural precision and patient outcomes.
End Use Segment Analysis: Hospitals and Clinics (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)
Holding the largest share of the drug-eluting balloon catheters market in 2026, hospitals and clinics remained the leading end-use segment. Their dominance is driven by the availability of specialized cardiovascular care, experienced interventional teams, and advanced imaging infrastructure required for complex vascular procedures. The ability to manage high patient volumes and provide comprehensive pre- and post-procedural care further reinforces their position as the primary treatment setting.
The ambulatory surgical centers segment is witnessing the fastest growth as healthcare systems increasingly shift suitable vascular interventions toward outpatient settings. Improvements in minimally invasive techniques, shorter recovery times, and the growing preference for cost-efficient treatment environments are encouraging greater utilization of these facilities. Continued expansion of outpatient cardiovascular services is expected to support sustained demand from ambulatory surgical centers.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters | Peripheral Vascular Disease Drug-Eluting Balloon Catheters | Coronary Artery Disease Drug-Eluting Balloon Catheters |
| Material | Polyurethane, Nylon, Others | Polyurethane | Polyurethane |
| End Use | Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories | Hospitals and Clinics | Ambulatory Surgical Centers |
Competitive Landscape and Market Positioning
Key companies in the drug-eluting balloon catheters market:
- Medtronic plc (Ireland)
- Boston Scientific Corporation (United States)
- B. Braun Melsungen AG (Germany)
- Biotronik SE & Co. KG (Germany)
- Becton Dickinson and Company (United States)
- Biosensors International Group Ltd. (Singapore)
- Terumo Corporation (Japan)
- Lepu Medical Technology (Beijing) Co., Ltd. (China)
- iVascular S.L.U. (Spain)
- MedAlliance SA (Switzerland)
Clinical differentiation has become a defining feature of competition in the drug-eluting balloon catheters market as manufacturers focus on improving drug delivery efficiency, coating stability, and procedural consistency across increasingly complex vascular interventions. Innovation is extending beyond the balloon platform itself to encompass delivery performance, lesion accessibility, and physician usability, reflecting growing demand for solutions that fit diverse treatment pathways. Regulatory expectations and expanding clinical evidence requirements are also raising competitive barriers, favoring developers with strong research capabilities and manufacturing precision. Market participants are increasingly competing through long-term clinical value supported by product reliability and procedural confidence rather than relying solely on incremental device modifications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Cardionovum | Oct-25 | Cardionovum secured commercial approval from ANVISA for its Aperto over-the-wire drug-coated balloon, facilitating patient access to advanced therapies designed to prolong arteriovenous fistula lifespan for dialysis patients. |
| Teleflex Incorporated | Jul-25 | Teleflex Incorporated entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK for an estimated cash payment of EUR 760 million, strengthening its strategic positioning and product portfolio in catheter-based interventions. |
| Cordis | Feb-25 | Cordis entered into a strategic collaboration with BrosMed to support the commercialization and market expansion of the VaSecure next-generation drug-coated balloon in China, aiming to enhance distribution channels and clinical adoption. |
| MicroPort | Feb-25 | MicroPort obtained regulatory approval in China for the Firelimus rapamycin drug-eluting balloon, expanding its advanced coronary intervention portfolio to target primary coronary bifurcation lesions. |
| Boston Scientific | Mar-24 | Boston Scientific received US FDA clearance for the AGENT drug-coated balloon, establishing a new clinical treatment option for coronary in-stent restenosis and strengthening its competitive footprint in vascular devices. |
| Cordis | Oct-23 | Cordis completed its acquisition of MedAlliance, strategically expanding its drug-eluting balloon portfolio by integrating SELUTION SLR sustained sirolimus technology. |
| Boston Scientific Corporation | Feb-22 | Boston Scientific Corporation completed the acquisition of Baylis Medical Company Inc., gaining transseptal access solutions, guidewires, and balloon dilators to expand its geographical presence and revenue base in catheter-based left-heart procedures. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Drug-Eluting Balloon Catheters Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Drug-Eluting Balloon Catheters Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of drug-eluting balloon catheters?
What are the growth projections for the drug-eluting balloon catheters industry?
How is the shift toward minimally invasive procedures influencing the drug-eluting balloon catheters market?
Why are technological advancements strengthening demand in the drug-eluting balloon catheters market?
Which product segment holds the largest share in the drug-eluting balloon catheters market?
Which end-use segment is growing the fastest in the drug-eluting balloon catheters market?
Why does North America hold the largest drug-eluting balloon catheters market share?
What is driving rapid growth of drug-eluting balloon catheters in Asia Pacific?
Which companies dominate the drug-eluting balloon catheters landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization